Naringin - CAS 10236-47-2
Catalog number:
10236-47-2
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C27H32O14
Molecular Weight:
580.53
COA:
Inquire
Targets:
Cytochrome P450
Description:
Naringin inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug interactions.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Naringoside
MSDS:
Inquire
1.Protective effect of Naringin on experimental hindlimb ischemia/reperfusion injury in rats.
Gürsul C1, Ekinci Akdemir FN2, Akkoyun T3, Can İ4, Gül M5, Gülçin İ6,7. J Enzyme Inhib Med Chem. 2016 Apr 7:1-6. [Epub ahead of print]
This study was designed to investigate the antioxidant effects of Naringin, in ischemia/reperfusion (I/R)-induced skeletal muscle injury in rats. The rats were randomly allocated into three groups including control, I/R and I/R + Naringin groups. Muscle tissues of I/R groups revealed significantly higher antioxidant enzyme activities, and increased levels of malondialdehyde, as specific a marker of the lipid peroxidation and tissue damage, compared to the control group (p < 0.05). Levels of these parameters in muscle revealed significant reductions in the I/R + Naringin group compared to the I/R group (p < 0.05). Histopathological examination of ischemia muscles in the I/R group showed significant degeneration and inflammation compared to the control group, whereas ischemic muscles of Naringin-administered group showed significant reduction in degeneration and inflammation compared to the I/R group (p < 0.05). We suggest that the protective effect of Naringin may reduce the I/R injury in cases of extremity injuries with acute vascular complications, extremity surgery with prolonged tourniquet application.
2.NEU3 inhibitory effect of naringin suppresses cancer cell growth by attenuation of EGFR signaling through GM3 ganglioside accumulation.
Yoshinaga A1, Kajiya N1, Oishi K1, Kamada Y1, Ikeda A1, Chigwechokha PK2, Kibe T3, Kishida M3, Kishida S3, Komatsu M2, Shiozaki K4. Eur J Pharmacol. 2016 Apr 19. pii: S0014-2999(16)30249-7. doi: 10.1016/j.ejphar.2016.04.035. [Epub ahead of print]
Naringin, which is one of the flavonoids contained in citrus fruits, is well known to possess various healthy functions to humans. It has been reported that naringin suppresses cancer cell growth in vitro and in vivo, although the underlying mechanisms are not fully understood. Recently, the roles of glycoconjugates, such as gangliosides, in cancer cells have been focused because of their regulatory effects of malignant phenotypes. Here, to clarify the roles of naringin in the negative-regulation of cancer cell growth, the alteration of glycoconjugates induced by naringin exposure and its significance on cell signaling were investigated. Human cancer cells, HeLa and A549, were exposed to various concentrations of naringin. Naringin treatment induced the suppression of cell growth toward HeLa and A549 cells accompanied with an increase of apoptotic cells. In naringin-exposed cells, GM3 ganglioside was drastically increased compared to the GM3 content prior to the treatment.
3.Ameliorative effect of naringin in acetaminophen-induced hepatic and renal toxicity in laboratory rats: role of FXR and KIM-1.
Adil M1, Kandhare AD1, Ghosh P1, Venkata S1, Raygude KS1, Bodhankar SL1. Ren Fail. 2016 Apr 6:1-14. [Epub ahead of print]
CONTEXT: Acetaminophen (APAP) is an analgesic and antipyretic agent commonly known agent to cause hepatic and renal toxicity at a higher dose. Naringin, a bioflavonoid possesses multiple pharmacological properties such as antioxidant, anti-inflammatory, analgesic and anti-hyperlipidemic activity.
4.In vitro effects of the citrus flavonoids diosmin, naringenin and naringin on the hepatic drug-metabolizing CYP3A enzyme in human, pig, mouse and fish.
Burkina V1, Zlabek V2, Halsne R3, Ropstad E4, Zamaratskaia G5. Biochem Pharmacol. 2016 Apr 20. pii: S0006-2952(16)30065-X. doi: 10.1016/j.bcp.2016.04.011. [Epub ahead of print]
Flavonoids are known to have effects on cytochrome P450 enzymatic activity. However, little effort has been made to examine species differences and the relevance of studies on mammalian and fish microsomes so that extrapolations can be made to humans. Therefore, the effects of several naturally occurring flavonoids on the activity of CYP3A-dependent 7-benzyloxy- 4-trifluoromethylcoumarinO-debenzylase (BFCOD) were evaluated in human, pig, mouse, and juvenile rainbow trout sources of hepatic microsomes. Each was exposed to three concentrations (1, 10, and 100 μM) diosmin, naringin, and naringenin. Naringenin competitively inhibited BFCOD activity (Ki values were 24.6 μM in human, 15.6 μM in pig, and19.6 μM in mouse microsomes). In fish, BFCOD activity was inhibited in a noncompetitive manner (Ki = 7 μM). Neither diosmin nor naringenin affected BFCOD activity in hepatic microsomes from the studied model organisms. These results suggest that dietary flavonoids potentially inhibit metabolism of clinical drugs.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cytochrome P450 Products


VT-464
(CAS: 1610537-15-9)

VT-464, also called as Seviteronel, is an oral, non-steroidal, lyase-selective CYP17 inhibitor to reach Phase II clinical trials in Breast cancer in USA (PO). i...

CAS 566939-85-3 Orteronel

Orteronel
(CAS: 566939-85-3)

Orterone (TAK-700) is an orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrog...

CAS 54-36-4 Metyrapone

Metyrapone
(CAS: 54-36-4)

Metyrapone acts as a glucocorticoid synthesis inhibitor, blocks cortisol synthesis by inhibiting steroid 11β-hydroxylase in adrenal cortex (IC50 = 7.8 μM).

CAS 10236-47-2 Naringin

Naringin
(CAS: 10236-47-2)

Naringin inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug i...

CAS 870093-23-5 Talarozole

Talarozole
(CAS: 870093-23-5)

Talarozole, a retinoic acid metabolism blocking agent (RAMBA), is a potent and selective inhibitor of cytochrome P450 26 to treat dermatalogical diseases includ...

Dafadine-A
(CAS: 1065506-69-5)

Dafadine-A, the first identified chemical inhibitor of DAF-9, could restrain the dauer formation, developmental timing and longevity in the nematodeCaenorhabdit...

CAS 851983-85-2 Galeterone

Galeterone
(CAS: 851983-85-2)

Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique ...

CAS 95-25-0 Chlorzoxazone

Chlorzoxazone
(CAS: 95-25-0)

Chlorzoxazone is a muscle-relaxing drug, and a probe for human liver cytochrome P-450IIE1.

CAS 154229-18-2 Abiraterone Acetate

Abiraterone Acetate
(CAS: 154229-18-2)

The acetate form of abiraterone, which blocks the synthesis of androgens by inhibiting CYP17A1.

UK 39671
(CAS: 85473-17-2)

UK 39671 is a cytochrome P-450 inhibitor

CAS 1093131-03-3 Veledimex S enantiomer

Veledimex S enantiomer
(CAS: 1093131-03-3)

Veledimex S enantiomer is the S enantiomer of veledimex which is an orally active small molecule diacylhydrazine and controls the expression of the target gene.

VT-1161
(CAS: 1340593-59-0)

VT-1161 is a 14-alpha demethylase inhibitor as a tetrazole antifungal agent originated by Viamet Pharmaceuticals. VT-1161 shows potent efficacy in treatment of ...

BMS-351
(CAS: 1370001-71-0)

BMS-351 is a selective and nonsteroidal CYP17A1 lyase inhibitor with good selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 has become a preclinical ca...

CAS 201410-53-9 Talarozole

Talarozole
(CAS: 201410-53-9)

Talarozole, a retinoic acid metabolism blocking agent (RAMBA), is a potent and selective inhibitor of cytochrome P450 26 to treat dermatalogical diseases includ...

CAS 56-54-2 Conquinine

Conquinine
(CAS: 56-54-2)

Conquinine is a Cytochrome P450 2D6 inhibitor. It is a dextrorotatory stereoisomer of quinine extracted from the bark of the Cinchona tree and similar plant spe...

CFG920
(CAS: 1260006-20-9)

CFG920 is a Steroid 17-alpha-hydroxylase inhibitor originated by Novartis. It has potential antiandrogen and antineoplastic activities. It may inhibit cell prol...

CAS 62-68-0 Proadifen Hydrochloride

Proadifen Hydrochloride
(CAS: 62-68-0)

Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM) and stimulate endothelial cell prostacyclin production.

VT-464 racemate
(CAS: 1375603-36-3)

The racemate form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor. IC50...

CAS 154229-19-3 Abiraterone

Abiraterone
(CAS: 154229-19-3)

Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. It is used to treat metastatic, castration-resistant prostate cancer.

CAS 50-52-2 Thioridazine

Thioridazine
(CAS: 50-52-2)

Thioridazine is an inhibitor of CYP1A2 and CYP3A2. It is a piperidine typical antipsychotic drug belonging to the phenothiazine drug group and was previously wi...

Chemical Structure

CAS 10236-47-2 Naringin

Quick Inquiry

Verification code

Featured Items